Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting
[May 04, 2021]
Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced three presentations, including one from a research collaboration, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held virtually May 11 – 14, 2021.
Editas Medicine Scientist Heather MacLeod, Ph.D., will speak at the ASGCT Gene Editing Workshop. Her presentation, The Development of CRISPR Based Medicines for the Treatment of Ocular Diseases, will be part of ASGCT’s pre-meeting program Moving Genome Editing to the Clinic: From Technology to Therapeutics. In addition, the Company is presenting preclinical data demonstrating therapeutically relevant levels of editing using a dual AAV CRISPR-Cas9 system as a therapeutic strategy for the treatment of retinitis pigmentosa 4 (RP4) on May 11.
Invited Talk: Title: The Development of CRISPR Based Medicines for the Treatment of Ocular Diseases Date and Time: Monday, May 10, 2021, 11:15 – 11:40 a.m. ET Session Title: Moving Genome Editing to the Clinic: from Technology to Therapeutics Session Type: Pre-Meeting Workshop
Poster Presentation: Title: Advances Toward a Dual AAV CRISPR-Cas9-based “Knockout and Replace” Strategy to Treat Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa Date and Time: Tuesday, May 11 2021, 8:00 – 10:00 a.m. ET
Session Title: Neurologic Diseases
Research Collaboration Poster Presentation (Editas Medicine Author): Title: AsCas12a Ultra Nuclease Facilitates the Rapid Generation of Therapeutic Cell Medicines Date and Time: Tuesday, May 11, 2021, 8:00 – 10:00 a.m. ET Session Title: Gene Targeting and Gene Correction
About Editas Medicine As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Forward-Looking Statements This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
